MTOR and prostate carcinoma: Recently, we have demonstrated that para-toluenesulfonamide is a potential anti-tumor agent which inhibits both the Akt-dependent and -independent mammalian target of rapamycin (mTOR)/p70S6 kinase (p70S6K) pathways in prostate cancers, and the disturbance of lipid raft and cholesterol contents also are involved in the para-toluenesulfonamide-mediated mechanism [15].